These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17713764)

  • 1. What can gallium-68 PET add to receptor and molecular imaging?
    Al-Nahhas A; Win Z; Szyszko T; Singh A; Khan S; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1897-901. PubMed ID: 17713764
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin receptor PET imaging with Gallium-68 labeled peptides.
    Win Z; Al-Nahhas A; Rubello D; Gross MD
    Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):244-50. PubMed ID: 17464267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
    [No Abstract]   [Full Text] [Related]  

  • 4. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.
    Wild D; Mäcke HR; Waser B; Reubi JC; Ginj M; Rasch H; Müller-Brand J; Hofmann M
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):724. PubMed ID: 15551131
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging.
    Ambrosini V; Nanni C; Fanti S
    PET Clin; 2014 Jul; 9(3):323-9. PubMed ID: 25030395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68 PET: a new frontier in receptor cancer imaging.
    Al-Nahhas A; Win Z; Szyszko T; Singh A; Nanni C; Fanti S; Rubello D
    Anticancer Res; 2007; 27(6B):4087-94. PubMed ID: 18225576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG and Beyond.
    De Ruysscher D; Haustermans K; Thorwarth D
    Recent Results Cancer Res; 2016; 198():163-73. PubMed ID: 27318686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiopeptides for Imaging and Therapy: A Radiant Future.
    Chatalic KL; Kwekkeboom DJ; de Jong M
    J Nucl Med; 2015 Dec; 56(12):1809-12. PubMed ID: 26514175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy.
    Sharma P; Kumar R; Alavi A
    PET Clin; 2015 Oct; 10(4):495-505. PubMed ID: 26384596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Applicability of the Metal Labeling of Biomolecules by the RIKEN Click Reaction: A Case Study with Gallium-68 Positron Emission Tomography.
    Nakamoto Y; Pradipta AR; Mukai H; Zouda M; Watanabe Y; Kurbangalieva A; Ahmadi P; Manabe Y; Fukase K; Tanaka K
    Chembiochem; 2018 Oct; 19(19):2055-2060. PubMed ID: 30066425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
    Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Bradykinin B1 Receptor with 68Ga-Labeled [des-Arg10]Kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake.
    Amouroux G; Pan J; Jenni S; Zhang C; Zhang Z; Hundal-Jabal N; Colpo N; Liu Z; Bénard F; Lin KS
    Mol Pharm; 2015 Aug; 12(8):2879-88. PubMed ID: 26101793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
    Smith DL; Breeman WA; Sims-Mourtada J
    Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?
    Basu S; Alavi A
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1527-9. PubMed ID: 17522857
    [No Abstract]   [Full Text] [Related]  

  • 19. PET-MRI synergy in molecular, functional and anatomical cancer imaging.
    Lucignani G
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1550-3. PubMed ID: 18481060
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development of Molecular Probes for Live Imaging of Cancer and Infectious Diseases].
    Fuchigami T
    Yakugaku Zasshi; 2019; 139(12):1531-1538. PubMed ID: 31787640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.